Lenalidomidă Terapia

Lenalidomide, the active ingredient in Lenalidomidă Terapia, is an immunomodulatory drug (IMiD) presented as an oral formulation for systemic use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), mantle‑cell lymphoma and follicular lymphoma, typically in adult patients.

GNH USA supplies Lenalidomidă Terapia as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Lenalidomidă Terapia (lenalidomide) is used in hematologic malignancies that involve abnormal plasma‑cell or lymphoid proliferation. - Multiple Myeloma: reduces disease progression and improves survival in patients with relapsed or refractory disease. - Myelodysplastic Syndromes (del(5q)): corrects cytopenias and decreases transfusion dependence. - Mantle Cell Lymphoma: induces tumor regression and prolongs progression‑free survival. - Follicular Lymphoma: enhances response rates when combined with other agents.

Lenalidomidă Terapia may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Neutropenia: lowered neutrophil count increasing infection risk. - Thrombocytopenia: reduced platelet levels leading to easy bruising. - Anemia: decreased red blood cells causing weakness. - Diarrhea: mild to moderate gastrointestinal upset. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: significant liver enzyme elevations. - Severe infections: opportunistic infections due to immune suppression.

When prescribing Lenalidomidă Terapia, clinicians should observe several safety precautions. - Blood count monitoring: perform complete blood counts regularly to detect neutropenia or thrombocytopenia. - Thrombotic risk assessment: evaluate for prior clotting events and consider prophylactic anticoagulation. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception for both sexes. - Renal and hepatic function: adjust therapy based on kidney and liver assessments. - Patient counseling: inform about signs of infection, bleeding, and skin reactions. - Store at below 25°C: keep in the original packaging, protect from moisture and direct light.

Lenalidomidă Terapia can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Live vaccines: risk of uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug levels. - NSAIDs: potential additive effect on platelet inhibition. - Antihypertensives: monitor blood pressure as lenalidomide can cause fluid shifts.